- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers of immunotherapy response in breast cancer beyond PD-L1
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 191, Issue 1, Pages 39-49
Publisher
Springer Science and Business Media LLC
Online
2021-10-22
DOI
10.1007/s10549-021-06421-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
- (2021) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
- (2021) Leisha A Emens et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Tumor mutational burden as a predictor of immunotherapy response in breast cancer
- (2021) Tess A. O’Meara et al. Oncotarget
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- (2021) Ajjai S. Alva et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
- (2021) Nuria Chic et al. JNCI-Journal of the National Cancer Institute
- LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
- (2021) G. Bianchini et al. ANNALS OF ONCOLOGY
- 129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial
- (2021) M.V. Dieci et al. ANNALS OF ONCOLOGY
- The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
- (2021) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene expression profiles of breast cancer metastasis according to organ site
- (2021) Fara Brasó‐Maristany et al. Molecular Oncology
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
- (2021) Thomas Powles et al. NATURE
- Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
- (2021) Fara Brasó-Maristany et al. Frontiers in Oncology
- Prevalence and mutational determinants of high tumor mutation burden in breast cancer
- (2020) R. Barroso-Sousa et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- APOBEC3B expression and its prognostic potential in breast cancer
- (2020) Yan Mao et al. Oncology Letters
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
- (2020) T. Karn et al. ANNALS OF ONCOLOGY
- 128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
- (2020) T. Bachelot et al. ANNALS OF ONCOLOGY
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- (2020) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
- (2020) Eric P. Winer et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature
- (2020) Saranya Chumsri et al. Journal of the National Comprehensive Cancer Network
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
- (2020) Naiyer A. Rizvi et al. JAMA Oncology
- Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
- (2020) C. Criscitiello et al. BREAST CANCER RESEARCH AND TREATMENT
- 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
- (2020) V.M.T. De Jong et al. ANNALS OF ONCOLOGY
- LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
- (2020) G. Bianchini et al. ANNALS OF ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- (2020) Leisha A Emens et al. LANCET ONCOLOGY
- A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases
- (2020) Richard S. P. Huang et al. MODERN PATHOLOGY
- Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
- (2020) Qu Zhang et al. Cancer Discovery
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer
- (2019) Rim S Kim et al. JNCI-Journal of the National Cancer Institute
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project.
- (2019) Diana M. Merino et al. JOURNAL OF CLINICAL ONCOLOGY
- IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.
- (2019) Romualdo Barroso-Sousa et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
- (2019) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort
- (2019) Angela S. Cheng et al. BREAST CANCER RESEARCH AND TREATMENT
- Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
- (2019) Andrew Georgiadis et al. CLINICAL CANCER RESEARCH
- Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
- (2019) Feng Wang et al. JAMA Oncology
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
- (2019) Carmine De Angelis et al. CLINICAL CANCER RESEARCH
- The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
- (2019) Diane Damotte et al. Journal of Translational Medicine
- High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities
- (2019) Ioannis A. Voutsadakis Targeted Oncology
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
- (2018) Shixiang Wang et al. ONCOGENE
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
- (2018) Aaron M. Goodman et al. JAMA Oncology
- Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
- (2018) Vinay Prasad et al. JAMA Oncology
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
- (2018) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types
- (2018) L Paré et al. ANNALS OF ONCOLOGY
- Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
- (2018) Luc Cabel et al. Nature Reviews Clinical Oncology
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient
- (2018) Carlo Fremd et al. Breast Care
- Next-Generation Sequencing–Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer
- (2018) Sounak Gupta et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
- (2017) Maria Vittoria Dieci et al. SEMINARS IN CANCER BIOLOGY
- Breast tissue, oral and urinary microbiomes in breast cancer
- (2017) Hannah Wang et al. Oncotarget
- Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
- (2017) Gloria Mittica et al. Oncotarget
- Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
- (2016) Y. Asano et al. BRITISH JOURNAL OF SURGERY
- Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
- (2016) B. Ingold Heppner et al. CLINICAL CANCER RESEARCH
- Microsatellite markers: what they mean and why they are so useful
- (2016) Maria Lucia Carneiro Vieira et al. GENETICS AND MOLECULAR BIOLOGY
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
- (2016) Celine Lefebvre et al. PLOS MEDICINE
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease
- (2016) Tina J. Hieken et al. Scientific Reports
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
- (2014) Svasti Haricharan et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Microbial Dysbiosis Is Associated with Human Breast Cancer
- (2014) Caiyun Xuan et al. PLoS One
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
- (2013) Steven A Roberts et al. NATURE GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search